RADIOLOGICAL OR NUCLEAR MEDICAL COUNTERMEASURE PRODUCT DEVELOPMENT SUPPORT (PDS)

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services, is soliciting proposals for a contract titled "Radiological or Nuclear Medical Countermeasure Product Development Support (PDS)." This contract aims to advance the development of medical countermeasures (MCMs) for diagnosing, preventing, and treating acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), including biodosimetric technologies to assess radiation exposure. The development efforts will support candidate products through various stages, from early research to post-marketing, towards FDA approval or licensure under the Animal Efficacy Rule. Contractors will collaborate closely with NIAID and federal partners, including the FDA, to facilitate product development. The contract will be awarded as an Indefinite Delivery, Indefinite Quantity (IDIQ) agreement for up to seven years, anticipated to begin around July 1, 2027. Task areas under this agreement include administrative and technical support, animal model and new approach methodologies development, efficacy testing of MCM candidates, non-clinical studies supporting regulatory submissions, chemistry, manufacturing and control (CMC) support, and Phase I clinical studies. Proposals will be evaluated based on the scientific rigor and soundness of their approach, organizational capability, and compliance with regulatory standards such as GLP, cGMP, and GCP. The solicitation will be available on SAM.gov from June 2, 2026, and submissions must be made electronically through NIAID’s eCPS website by the deadline on June 2, 2026. The government does not guarantee contract award, and only online submissions are accepted.